Evidence map›Paper›PMID 35019128›Full record

ArticleArquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery2022

ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS.

Juliana Silveira Lima de Castro, Adriane Graicer Pelosof, João Guilherme Guerra de Andrade-Cabral, Alvaro Moura Seraphim, Eloy Taglieri, Felipe Jose Fernandez Coimbra, Claudia Zitron

Open access · diamondAbstract read
In one paragraph

Article in Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. HOSPITAL VOLUME, POSTOPERATIVE MORTALITY, AND COSTS AFTER GASTRECTOMY FOR GASTRIC CANCER IN COLOMBIA: IS THERE ANY ASSOCIATION?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2023
    Article
  2. OLIGOMETASTASIS IN GASTRIC CANCER TREATMENT: IS THERE A PLACE FOR THE SURGEON?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Juliana Silveira Lima de CastroA.C. Camargo Cancer Center, Endoscopy Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-0280-8356
Adriane Graicer PelosofA.C. Camargo Cancer Center, Endoscopy Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-9813-5832
João Guilherme Guerra de Andrade-CabralA.C. Camargo Cancer Center, Endoscopy Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-7607-6982
Alvaro Moura SeraphimA.C. Camargo Cancer Center, Endoscopy Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-3300-0467
Eloy TaglieriA.C. Camargo Cancer Center, Endoscopy Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-1039-793X
Felipe Jose Fernandez CoimbraA.C. Camargo Cancer Center, Gastrointestinal Surgical Oncology Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-5068-0639
Claudia ZitronA.C. Camargo Cancer Center, Endoscopy Unit, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-9364-8460
AC Camargo Hospital · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric and esophagogastric junction adenocarcinoma are responsible for approximately 13.5% of cancer-related deaths. Given the fact that these tumors are not typically detected until they are already in the advanced stages, neoadjuvancy plays a fundamental role in improving long-term survival. Identification of those with complete pathological response (pCR) after neoadjuvant chemotherapy (NAC) is a major challenge, with effects on organ preservation, extent of resection, and additional surgery. There is little or no information in the literature about which endoscopic signs should be evaluated after NAC, or even when such re-evaluation should occur.

aimTo describe the endoscopic aspects of patients with gastric and esophagogastric junction adenocarcinomas who underwent NAC and achieved pCR, and to determine the accuracy of esophagogastroduodenoscopy (EGD) in predicting the pCR.

methodsA survey was conducted of the medical records of patients with these tumors who were submitted to gastrectomy after NAC, with anatomopathological result of pCR.

resultsTwenty-nine patients were identified who achieved pCR after NAC within the study period. Endoscopic responses were used to classify patients into two groups: G1-endoscopic findings consistent with pCR and G2-endoscopic findings not consistent with pCR. Endoscopic evaluation in G1 was present in an equal percentage (47.4%; p=0.28) in Borrmann classification II and III. In this group, the predominance was in the gastric body (57.9%; p=0.14), intestinal subtype with 42.1% (p=0.75), undifferentiated degree, 62.5% (p=0.78), Herb+ in 73.3% (p=0.68). The most significant finding, however, was that the time interval between NAC and EGD was longer for G1 than G2 (24.4 vs. 10.2 days, p=0.008).

conclusionEGD after NAC seems to be a useful tool for predicting pCR, and it may be possible to use it to create a reliable response classification. In addition, the time interval between NAC and EGD appears to significantly influence the predictive power of endoscopy for pCR.

Indexed as

AdenocarcinomaStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsEndoscopyEsophagogastric JunctionHumansNeoadjuvant TherapyNeoplasm StagingTreatment Outcome

Identifiers

PMID35019128
PMCPMC8735268
OpenAlexW4205714446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.